Phase II Study Of Erlotinib As Third-Line Monotherapy In Patients With Advanced Non-Small-Cell Lung Cancer Without Epidermal Growth Factor Receptor Mutations

収録刊行物

• C43. LUNG CANCER: DIAGNOSIS, STAGING, TREATMENT AND OUTCOMES

  C43. LUNG CANCER: DIAGNOSIS, STAGING, TREATMENT AND OUTCOMES A4408-A4408, 2012-05-01

  American Thoracic Society